NeoRx' Verluma for initial small-cell lung cancer staging recommended for approval.
This article was originally published in The Gray Sheet
Executive Summary
NEORX' VERLUMA AGENT 82% ACCURATE IN STAGING SMALL-CELL LUNG CANCER, leading FDA's Oncologic Drugs Advisory Committee to recommend approval of the imaging diagnostic for initial staging of SCLC. The monoclonal antibody imaging agent (technetium 99m nofetumomab merpentan) accurately staged 73 of 89 small-cell lung cancer patients with a positive biopsy (82%) compared to 80 of 89 (90%) with the standard tests.